Aquamin® for Ulcerative Colitis

Recruiting in Palo Alto (17 mi)

Overseen byJames Varani

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: James Varani

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing Aquamin®, a seaweed-based supplement rich in minerals, to see if it can help people with mild Ulcerative Colitis feel better and stay symptom-free. The study focuses on patients who have mild symptoms or are already in remission. The idea is that the minerals in Aquamin® might reduce gut inflammation.

Eligibility Criteria

This trial is for individuals with mild Ulcerative Colitis or those in stable remission, confirmed by tests. Participants must not have used steroids, antibiotics, or certain supplements recently and should not be pregnant. Those with Crohn's disease, bleeding disorders, kidney issues including stones, high calcium levels, or on blood thinners like Coumadin are excluded.

Inclusion Criteria

My ulcerative colitis is in remission or mild, and I've been stable for 3+ months with or without maintenance therapy (no steroids/antibiotics).

A negative pregnancy test

Exclusion Criteria

I do not have Crohn's, bleeding disorders, certain cancers, kidney disease, high calcium levels, or blood clotting disorders, and I'm not on high doses of blood thinners.

I have taken calcium, vitamin D, fiber supplements, or NSAIDs in the last 30 days.

Participant Groups

The study is testing Aquamin®, a marine-sourced supplement to see if it can improve symptoms of Ulcerative Colitis and help maintain remission. Participants will either receive Aquamin® or a placebo initially followed by Aquamin® to compare the effects.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Aquamin®Experimental Treatment1 Intervention

To be taken for 180 days

Group II: Placebo first then Aquamin®Placebo Group2 Interventions

Placebo: To be taken for the first 90 days. Aquamin®: To be taken for the last 90 days (after crossover)